A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial to Establish the Efficacy and Safety of Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis
Latest Information Update: 16 Apr 2023
At a glance
- Drugs Aminopterin (Primary)
- Indications Psoriasis
- Focus Therapeutic Use
- Sponsors Syntrix Biosystems
- 15 Feb 2021 Status changed from active, no longer recruiting to completed.
- 16 Sep 2020 Status changed from recruiting to active, no longer recruiting.
- 14 May 2020 Planned End Date changed from 1 Mar 2021 to 1 May 2021.